Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Denali Therapeutics Inc. (DNLI) PT Lowered to $22 at Stifel
May 8, 2024 6:17 AM EDTStifel analyst Paul Mattels lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $22.00 (from $26.00) while maintaining a Hold rating.
The analyst comments "Most importantly, DNLI is noting now that CDER "may be open to discussing an accelerated path" for... More
